Logo

Genentech Reports Results of Vabysmo and Susvimo in P-III (YOSEMITE/ RHINE/ Archway) Studies for the Treatment of DME & AMD

Share this

Genentech Reports Results of Vabysmo and Susvimo in P-III (YOSEMITE/ RHINE/ Archway) Studies for the Treatment of DME & AMD

Shots:

  • The P-III (YOSEMITE/ RHINE & Archway) studies evaluate Vabysmo & Susvimo in 1,891 (YOSEMITE & RHINE) & 415 (Archway) for IV use via ocular implant in patients with DME & AMD, respectively
  • In (YOSEMITE & RHINE) studies, 60% & 64.5% achieved q4mos. dosing @2yrs., 80% of patients could extend treatment to q3mos. @2yrs., 42.8% & 44.3% achieved a two-step improvement from baseline along with 51.4% & 53.5% improvement in diabetic retinopathy severity. In the Archway study, 95% of susvimo patients maintained a 6mos. treatment @2yrs.
  • In all studies with longer follow-up, Vabysmo & Susvimo was well tolerated with favorable benefit-risk profiles & the safety will be monitored closely in the post-market setting

Ref: Businesswire | Image: Clinical Trial Arena

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions